Biolinq Shine Wins FDA Clearance as Needle-Free Glucose Wearable
The FDA granted 510(k) clearance for Biolinq Shine, a needle-free wearable that monitors glucose, activity, and sleep in one device.
The U.S. Food and Drug Administration has granted 510(k) clearance for Biolinq Shine, a consumer wearable device that monitors blood glucose levels without the use of needles, the company announced. The clearance marks a regulatory milestone for over-the-counter glucose monitoring technology aimed at the general public.
Biolinq Shine is positioned as the first needle-free wearable to combine continuous glucose tracking with activity and sleep monitoring in a single device. Traditional continuous glucose monitors typically require a small sensor filament inserted under the skin, making Shine's non-invasive approach a notable departure from existing products on the market.
Read more HouseCanary Wins Court Approval for Chapter 11 Reorganization Financing →
The 510(k) pathway, which the FDA uses to clear medical devices that are substantially equivalent to legally marketed predicate devices, signals that Biolinq Shine meets federal safety and effectiveness standards for over-the-counter use. Clearance for OTC sale means consumers can purchase the device without a prescription, potentially broadening access to glucose monitoring beyond the diabetic patient population.
The convergence of glucose tracking, physical activity measurement, and sleep analysis in one wearable platform reflects a broader industry trend toward integrated health monitoring. Analysts have noted growing consumer demand for devices that consolidate health metrics without invasive components, and FDA clearance lends Biolinq Shine a significant competitive advantage in that emerging segment.
Continue reading at GlobeNewswire - Industry News on Financial Services.
